Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Academic Article uri icon

Overview

abstract

  • A total of 28 treatment-na├»ve patients with stage II or III multiple myeloma (MM) were treated with the combination of clarithromycin, lenalidomide, and dexamethasone (BiRD). Stem cells were collected following granulocyte-colony stimulating factor (G-CSF) or cyclophosphamide (Cy) plus G-CSF mobilization at maximum response. Sufficient stem cells for 2 autologous stem cell transplants were collected from all patients mobilized with Cy plus G-CSF, versus 33% mobilized with G-CSF alone (P < .0001). The duration of prior lenalidomide therapy did not correlate with success of stem cell harvests (P = .91). In conclusion, Cy can be added to G-CSF for stem cell mobilization to successfully overcome the suppressive effect of prior treatment with lenalidomide.

publication date

  • July 1, 2008

Research

keywords

  • Antineoplastic Combined Chemotherapy Protocols
  • Cyclophosphamide
  • Hematinics
  • Hematopoietic Stem Cell Mobilization
  • Hematopoietic Stem Cell Transplantation
  • Multiple Myeloma
  • Thalidomide

Identity

PubMed Central ID

  • PMC3626097

Scopus Document Identifier

  • 44649202066

Digital Object Identifier (DOI)

  • 10.1016/j.bbmt.2008.04.008

PubMed ID

  • 18541199

Additional Document Info

volume

  • 14

issue

  • 7